

DAFTAR PUSTAKA

- Al Harbi, R., McNeish, I.A., & El-Bahrawy, M., 2021. Ovarian sex cord-stromal tumors: An update on clinical features, molecular changes, and management. *Int. J. Gynecol. Cancer* 31: 161–168.
- Andreeff, M., Goodrich, D.W., & Pardee, A.B., 2003. Proliferation, in: Holland-Frei Cancer Medicine 6th Edition. BC Decker, Hamilton.
- Barnum, K.J., & O’Connell, M.J., 2014. Cell Cycle Regulation by Checkpoints. pp. 29–40.
- Baschong, W., Suetterlin, R., & Laeng, R.H., 2001. Control of Autofluorescence of Archival Formaldehyde-fixed, Paraffin-embedded Tissue in Confocal Laser Scanning Microscopy (CLSM). *J. Histochem. Cytochem.* 49: 1565–1571.
- Blay, J.-Y., Coindre, J.-M., Ducimetière, F., & Ray-Coquard, I., 2016. The value of research collaborations and consortia in rare cancers. *Lancet Oncol.* 17: e62–e69.
- Boussios, S., Moschetta, M., Zarkavelis, G., Papadaki, A., Kefas, A., & Tatsi, K., 2017. Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. *Crit. Rev. Oncol. Hematol.* 120: 43–51.
- Brown, J., Friedlander, M., Backes, F.J., Harter, P., O’Connor, D.M., de la Motte Rouge, T., et al., 2014. Gynecologic Cancer Intergroup (GCIg) Consensus Review for Ovarian Germ Cell Tumors. *Int. J. Gynecol. Cancer* 24: S48–S54.
- Brown, L.A., & Huntsman, D., 2007. Fluorescent in situ hybridization on tissue microarrays: challenges and solutions. *J. Mol. Histol.* 38: 151–157.
- Casteel, C.O., & Singh, G., 2023. Physiology, Gonadotropin-Releasing Hormone, StatPearls.
- Chen, C.-P., & Lu, X., 2022. Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis. *J. Int. Med. Res.* 50: 030006052210828.
- Cheng, C.K., & Leung, P.C.K., 2005. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. *Endocr. Rev.* 26: 283–306.
- Cheung, A., Shah, S., Parker, J., Soor, P., Limbu, A., Sheriff, M., et al., 2022. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? *Int. J. Environ. Res. Public Health* 19: 1106.
- Cheung, L.W.T., & Wong, A.S.T., 2008. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. *FEBS J.* 275: 5479–5495.
- Choi, J.-H., Gilks, C.B., Auersperg, N., & Leung, P.C.K., 2006. Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. *J. Clin. Endocrinol. Metab.* 91: 4562–4570.
- Choi, K.-C., Auersperg, N., & Leung, P.C.K., 2001. Expression and Antiproliferative Effect of a Second Form of Gonadotropin-Releasing Hormone in Normal and Neoplastic Ovarian Surface Epithelial Cells. *J. Clin. Endocrinol. Metab.* 86: 5075–5075.

- Cormio, G., Loizzi, V., Falagario, M., Scardigno, D., E., L., & Latorre, D., 2013. Borderline Epithelial Tumors of the Ovary, in: Ovarian Cancer - A Clinical and Translational Update. InTech.
- Dahlan, M.S., 2013. Statistik untuk Kedokteran dan Kesehatan Edisi 5. Salemba Medika, Jakarta.
- Desaulniers, A.T., Cederberg, R.A., Lents, C.A., & White, B.R., 2017. Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals. *Front. Endocrinol. (Lausanne)*. 8.
- Dzulkifli, F.A., & Mashor, M.Y., 2018. An overview of recent counting methods for Ki67 IHC staining. *J Biomed Clin Sci* 3: 10–17.
- Edge, S.B., & Compton, C.C., 2010. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. *Ann. Surg. Oncol.* 17: 1471–1474.
- Emons, G., Weiss, S., Ortmann, O., Grundker, C., & Schulz, K., 2000. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. *Eur. J. Endocrinol.* 665–670.
- Endl, E., & Gerdes, J., 2000. The Ki-67 Protein: Fascinating Forms and an Unknown Function. *Exp. Cell Res.* 257: 231–237.
- Enomoto, M., Endo, D., Kawashima, S., & Park, M.K., 2004. Human type II GnRH receptor mediates effects of GnRH on cell proliferation. *Zoolog. Sci.* 21: 763–770.
- Fischerova, D., Zikan, M., Dundr, P., & Cibula, D., 2012. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. *Oncologist* 17: 1515–1533.
- Fontana, F., Marzagalli, M., Montagnani Marelli, M., Raimondi, M., Moretti, R.M., & Limonta, P., 2020. Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. *Int. J. Mol. Sci.* 21.
- Gatta, G., van der Zwan, J.M., Casali, P.G., Siesling, S., Dei Tos, A.P., Kunkler, I., et al., 2011. Rare cancers are not so rare: The rare cancer burden in Europe. *Eur. J. Cancer* 47: 2493–2511.
- Ghaly, H.S.A., & Varamini, P., 2021. New drug delivery strategies targeting the GnRH receptor in breast and other cancers. *Endocr. Relat. Cancer* 28: R251–R269.
- Gil-Martin, M., Pardo, B., & Barretina-Ginesta, M.-P., 2020. Rare ovarian tumours. Other treatments for ovarian cancer. *Eur. J. Cancer Suppl.* 15: 96–103.
- Gründker, C., & Emons, G., 2021. Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer. *Cells* 10: 437.
- Gründker, C., Günthert, A.R., Millar, R.P., & Emons, G., 2002. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. *J. Clin. Endocrinol. Metab.* 87: 1427–1430.
- Hanley, K.Z., & Mosunjac, M.B., 2019. Practical Review of Ovarian Sex Cord–Stromal Tumors. *Surg. Pathol. Clin.* 12: 587–620.
- Haroon, S., Zia, A., Idrees, R., Memon, A., Fatima, S., & Kayani, N., 2013. Clinicopathological spectrum of ovarian sex cord-stromal tumors; 20 years' retrospective study in a developing country. *J. Ovarian Res.* 6: 87.
- Harrison, G.S., Wierman, M.E., Nett, T.M., & Glode, L.M., 2004. Gonadotropin-

- releasing hormone and its receptor in normal and malignant cells. *Endocr. Relat. Cancer* 11: 725–748.
- Hauptmann, S., Friedrich, K., Redline, R., & Avril, S., 2017. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. *Virchows Arch.* 470: 125–142.
- Huang, F., Wang, H., Zou, Y., Liu, Q., Cao, J., & Yin, T., 2013. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. *Int. J. Clin. Exp. Pathol.* 6: 2487–96.
- Irving, J.A., Lee, C.-H., Yip, S., Oliva, E., McCluggage, W.G., & Young, R.H., 2015. Microcystic Stromal Tumor. *Am. J. Surg. Pathol.* 39: 1420–1426.
- Isberg, V., De Graaf, C., Bortolato, A., Cherezov, V., Katritch, V., Marshall, F.H., et al., 2015. Generic GPCR residue numbers—aligning topology maps while minding the gaps. *Trends Pharmacol. Sci.* 36: 22–31.
- Iscar, T., Arian, C., Chiva, L., & Sanz, J., 2021. Ovarian yolk sac tumor. *Int. J. Gynecol. Cancer* 31: 797–798.
- Kang, S.K., Choi, K.-C., Yang, H.-S., & Leung, P.C.K., 2003. Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. *Endocr. Relat. Cancer* 169–177.
- Kaur, B., 2020. Pathology of malignant ovarian germ cell tumours. *Diagnostic Histopathol.* 26: 289–297.
- Khonsa, O., Nuranna, L., & Sutrisna, B., 2007. kesintasan pasien karsinoma ovarium dan faktor-faktor yang mempengaruhinya di RSUPN dr.cipto mangunkusumo jakarta (pemantauan 5 tahun). *Inajog* 8.
- Khouja, M.H., Baekelandt, M., Sarab, A., Nesland, J.M., & Holm, R., 2010. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. *Oncol. Lett.* 1: 827–831.
- Kononen, J., Bubendorf, L., Kallionimeni, A., Bärklund, M., Schraml, P., Leighton, S., et al., 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat. Med.* 4: 844–847.
- Le Page, C., Mes-Masson, A.-M., & Magliocco, A.M., 2014. Tissue Microarrays in Studying Gynecological Cancers, in: *Cancer Genomics*. Elsevier, pp. 65–76.
- Lee, G., & Ge, B., 2010. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor. *Cancer Immunol. Immunother.* 59: 1011–1019.
- Lee, S.-H., Kim, T.-H., Lee, H.-H., Lee, A., Kim, Y.-S., Jeon, D.-S., et al., 2015. Mucinous Borderline Ovarian Tumor in Very Old Aged Postmenopausal Woman. *J. Menopausal Med.* 21: 160.
- Li, J., Bao, R., Peng, S., & Zhang, C., 2018. The molecular mechanism of ovarian granulosa cell tumors. *J. Ovarian Res.* 11: 13.
- LI, L.T., JIANG, G., CHEN, Q., & ZHENG, J.N., 2015. Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Mol. Med. Rep.* 11: 1566–1572.
- Limonta, P., & Manea, M., 2013. Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. *Cancer Treat. Rev.* 39: 647–663.

- Limonta, P., Marelli, M.M., Mai, S., Motta, M., Martini, L., & Moretti, R.M., 2012. GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies. *Endocr. Rev.* 33: 784–811.
- López-Reig, R., & López-Guerrero, J.A., 2020. The hallmarks of ovarian cancer: proliferation and cell growth. *Eur. J. Cancer Suppl.* 15: 27–37.
- Lu, M., Zhu, J., Ling, Y., Shi, W., Zhang, C., & Wu, H., 2015. The lower expression of gonadotropin-releasing hormone receptor associated with poor prognosis in gastric cancer. *Int. J. Clin. Exp. Med.* 8: 13365–70.
- Mahadevappa, A., 2017. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. *J. Clin. Diagnostic Res.* 11: EC08-EC12.
- Marelli, M., Moretti, R., Januszkiewicz-Caulier, J., Motta, M., & Limonta, P., 2006. Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients? *Curr. Cancer Drug Targets* 6: 257–269.
- McIntosh, J.R., 2016. Mitosis. *Cold Spring Harb. Perspect. Biol.* 8: a023218.
- Millar, R.P., 2003. GnRH II and type II GnRH receptors. *Trends Endocrinol. Metab.* 14: 35–43.
- Miller, D.S., Scambia, G., Bondarenko, I., Westermann, A.M., Oaknin, A., Oza, A.M., et al., 2018. ZoptEC: Phase III randomized controlled study comparing zoletarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). *J. Clin. Oncol.* 36: 5503–5503.
- Miller, R.C., 2010. Problems in rare tumor study: a call for papers. *Rare Tumors* 2: 46–47.
- Montagnani Marelli, M., Moretti, R.M., Mai, S., Januszkiewicz-Caulier, J., Motta, M., & Limonta, P., 2009. Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells. *J. Clin. Endocrinol. Metab.* 94: 1761–1767.
- Moretti, R.M., Mai, S., Montagnani Marelli, M., Bani, M.R., Ghilardi, C., Giavazzi, R., et al., 2010. Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. *Endocrinology* 151: 4643–4653.
- Naor, Z., & Huhtaniemi, I., 2013. Interactions of the GnRH receptor with heterotrimeric G proteins. *Front. Neuroendocrinol.* 34: 88–94.
- National Cancer Institute, 2022. Cell proliferation [WWW Document]. URL <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cell-proliferation> (accessed 1.2.23).
- National Library of Medicine (US), 2023. GNRHR2 gonadotropin releasing hormone receptor 2 (pseudogene) [Homo sapiens (human)] [WWW Document]. URL <https://www.ncbi.nlm.nih.gov/gene/114814> (accessed 5.28.23).
- Parborell, F., Irusta, G., Rodríguez Celín, A., & Tesone, M., 2008. Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. *Mol. Reprod. Dev.* 75: 623–631.
- Prat, J., 2017. Pathology of borderline and invasive cancers. *Best Pract. Res. Clin.*

- Obstet. Gynaecol.* 41: 15–30.
- Ray-Coquard, I., Pujade Lauraine, E., Le Cesne, A., Pautier, P., Vacher Lavenue, M.C., Trama, A., et al., 2017. Improving treatment results with reference centres for rare cancers: where do we stand? *Eur. J. Cancer* 77: 90–98.
- Ruengwanichayakun, P., 2021. Histochemical scoring assessment (H-score). *Asian Arch. Pathol.* 13: 13–14.
- Shi, P., Zhong, J., Hong, J., Huang, R., Wang, K., & Chen, Y., 2016. Automated Ki-67 Quantification of Immunohistochemical Staining Image of Human Nasopharyngeal Carcinoma Xenografts. *Sci. Rep.* 6: 32127.
- Sinha, T., 2018. Tumors: Benign and Malignant. *Cancer Ther. Oncol. Int. J.* 10.
- Skírnisdóttir, I., Garmo, H., Wilander, E., & Holmberg, L., 2008. Borderline ovarian tumors in Sweden 1960-2005: Trends in incidence and age at diagnosis compared to ovarian cancer. *Int. J. Cancer* 123: 1897–1901.
- Sultan Aldrees, P.Z., 2015. Gonadotropin-Releasing Hormone Receptor is expressed in Retinoblastoma. *J. Clin. Exp. Pathol.* 05.
- Sun, X., & Kaufman, P.D., 2018. Ki-67: more than a proliferation marker. *Chromosoma* 127: 175–186.
- Sun, Y., Xu, J., & Jia, X., 2020. The diagnosis, treatment, prognosis and molecular pathology of borderline ovarian tumors: Current status and perspectives. *Cancer Manag. Res.* 12: 3651–3659.
- Suo, L., Chang, X., Xu, N., & Ji, H., 2019. The Anti-proliferative Activity of GnRH Through Downregulation of the Akt/ERK Pathways in Pancreatic Cancer. *Front. Endocrinol. (Lausanne)*. 10.
- Takagi, M., Nishiyama, Y., Taguchi, A., & Imamoto, N., 2014. Ki67 Antigen Contributes to the Timely Accumulation of Protein Phosphatase 1 γ on Anaphase Chromosomes. *J. Biol. Chem.* 289: 22877–22887.
- Thrall, M.M., Paley, P., Pizer, E., Garcia, R., & Goff, B.A., 2011. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. *Gynecol. Oncol.* 122: 242–245.
- Ulm, M., Ramesh, A. V, McNamara, K.M., Ponnusamy, S., Sasano, H., & Narayanan, R., 2019. Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. *Endocr. Connect.* 8: R10–R26.
- Varghese, F., Bukhari, A.B., Malhotra, R., & De, A., 2014. IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples. *PLoS One* 9: e96801.
- Vicus, D., Beiner, M.E., Klachook, S., Le, L.W., Laframboise, S., & Mackay, H., 2010. Pure dysgerminoma of the ovary 35 years on: A single institutional experience. *Gynecol. Oncol.* 117: 23–26.
- Voduc, D., Kenney, C., & Nielsen, T.O., 2008. Tissue Microarrays in Clinical Oncology. *Semin. Radiat. Oncol.* 18: 89–97.
- Walkiewicz, D., Wicik, Z., & Puzianowska-Kuznicka, M., 2021. Gonadotropin-releasing hormone receptor pathway affects the function of human EBV-transformed B lymphocytes in an age-independent way. *Exp. Gerontol.* 152: 111471.
- Wang, Y., Yang, J., Yu, M., Cao, D., & Shen, K., 2018. Malignant mixed ovarian

germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma harboring an EGFR mutation: a case report. *Oncotargets. Ther.* Volume 11: 6853–6862.

Wang, Z., 2021. Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling. *Cells* 10: 3327.

WHO Classification of Tumours Editorial Board, 2021. Female Genital Tumours: WHO Classification of Tumours 5th ed. IARC, Lyon.

Wicaksono, A.W., 2023. Korelasi Ekspresi Reseptor GnRH Tipe-II dengan Aktivitas Proliferasi dan Klinikopatologi Pada Kanker Ovarium Epitelial. Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan.

World Health Organization, 2020. WHO Classification of Tumor Female Genital Tumor 5th Edition. WHO Press, Geneva.

Zucha, M.A., Dewanto, A., Widad, S., Taufiqurrachman, I., Kusumanto, A., Pangastuti, N., et al., 2022. Expression of GnRH Receptor Type-II Correlates with Proliferation Activity in Endometriosis. *Int. J. Infertil. Fetal Med.* 13: 35–39.